Menu Search
Equities

Masimo Corp

MASI:NSQ

Masimo Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)171.38
  • Today's Change2.26 / 1.33%
  • Shares traded196.10k
  • 1 Year change+84.99%
  • Beta0.9939
Data delayed at least 15 minutes, as of Nov 22 2024 16:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Masimo Corp's net income fell -43.21% from 143.50m to 81.50m despite flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 47.99% to 51.00%.
Gross margin50.05%
Net profit margin3.85%
Operating margin6.68%
Return on assets2.58%
Return on equity5.74%
Return on investment3.23%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Masimo Corp fell by 41.40m. However, the company earned 94.10m from its operations for a Cash Flow Margin of 4.59%. In addition the company used 81.20m on investing activities and also paid 57.10m in financing cash flows.
Cash flow per share3.20
Price/Cash flow per share52.25
Book value per share27.35
Tangible book value per share7.66
More ▼

Balance sheet in USDView more

Masimo Corp has a Debt to Total Capital ratio of 34.56%, a lower figure than the previous year's 71.35%.
Current ratio2.01
Quick ratio1.11
Total debt/total equity0.528
Total debt/total capital0.3456
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -42.05%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-15.37
EPS (TTM) vs
TTM 1 year ago		-11.03
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.